La cadena de opciones muestra datos clave de las opciones de acciones de Biomea Fusion a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Biomea Fusion..

Biomea Fusion (NASDAQ:BMEA) Bolsa, Cadena de Opciones

BIOMEA FUSION INC

Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Biomea Fusion Inc

News

Press Releases

General

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Management

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Earnings

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Health Care

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Financing

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

BMEA

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Entera Bio

EXoZymes

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

TuHURA Biosciences

InflaRx

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immix Biopharma

Opus Genetics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Macrogenics

Metagenomi

Ovid Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

AVITA Medical

Surrozen

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

D. Boral Capital

Jefferies

Citigroup

Scotiabank

Piper Sandler

Comments

Biomea Fusion

Biomea Fusion (BMEA) Opciones

Biomea Fusion (NASDAQ:BMEA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL